• Je něco špatně v tomto záznamu ?

Treatment of chronic myelomonocytic leukemia with 5-azacytidine: case reports

P. Rohon, J. Vondrakova, A. Jonasova, M. Holzerova, M. Jarosova, K. Indrak,

. 2012 ; 2012 () : 369086.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu kazuistiky

Perzistentní odkaz   https://www.medvik.cz/link/bmc13016073

Grantová podpora
NT12218 MZ0 CEP - Centrální evidence projektů

Epigenetic therapy with hypomethylating agent (5-azacytidine; AZA) is common in the management of specific subtypes of myelodysplastic syndrome (MDS), but there are only few studies in chronic myelomonocytic leukemia (CMML) patients. In this paper our experience with 3 CMML patients treated with AZA is described. In one patient transfusion independency was observed after 4 treatment cycles; in one case a partial response was recorded, but a progression to acute myeloid leukemia (AML) after 13 AZA cycles has appeared. In one patient, AZA in reduced dosage was administered as a bridging treatment before allogeneic stem cell transplantation (ASCT), but in the control bone marrow aspirate (before ASCT) a progression to AML was recorded. Future studies are mandatory for evaluation of new molecular and clinical features which could predict the efficiency of hypomethylating agents in CMML therapy with respect to overall survival, event-free survival, quality-adjusted life year, and pharmacoeconomy.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc13016073
003      
CZ-PrNML
005      
20170524102211.0
007      
ta
008      
130424s2012 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1155/2012/369086 $2 doi
035    __
$a (PubMed)22937326
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Rohoň, Peter $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky' University, Olomouc, IP Pavlova 6, 775 20 Olomouc, Czech Republic. $7 ola2009507853
245    10
$a Treatment of chronic myelomonocytic leukemia with 5-azacytidine: case reports / $c P. Rohon, J. Vondrakova, A. Jonasova, M. Holzerova, M. Jarosova, K. Indrak,
520    9_
$a Epigenetic therapy with hypomethylating agent (5-azacytidine; AZA) is common in the management of specific subtypes of myelodysplastic syndrome (MDS), but there are only few studies in chronic myelomonocytic leukemia (CMML) patients. In this paper our experience with 3 CMML patients treated with AZA is described. In one patient transfusion independency was observed after 4 treatment cycles; in one case a partial response was recorded, but a progression to acute myeloid leukemia (AML) after 13 AZA cycles has appeared. In one patient, AZA in reduced dosage was administered as a bridging treatment before allogeneic stem cell transplantation (ASCT), but in the control bone marrow aspirate (before ASCT) a progression to AML was recorded. Future studies are mandatory for evaluation of new molecular and clinical features which could predict the efficiency of hypomethylating agents in CMML therapy with respect to overall survival, event-free survival, quality-adjusted life year, and pharmacoeconomy.
650    12
$a chronická myelomonocytární leukemie $x farmakoterapie $7 D015477
650    12
$a azacytidin $7 D001374
650    _2
$a lidé $7 D006801
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a senioři $7 D000368
650    _2
$a ženské pohlaví $7 D005260
655    _2
$a kazuistiky $7 D002363
700    1_
$a Vondráková, Jana $7 xx0106447
700    1_
$a Jonášová, Anna $7 xx0103767
700    1_
$a Holzerová, Milena $7 xx0060567
700    1_
$a Jarošová, Marie, $d 1950- $7 xx0053403
700    1_
$a Indrák, Karel, $d 1947- $7 jn20000401162
773    0_
$w MED00181388 $t Case reports in hematology $x 2090-6579 $g Roč. 2012(2012), s. 369086
856    41
$u https://pubmed.ncbi.nlm.nih.gov/22937326 $y Pubmed
910    __
$a ABA008 $b sig $y 4 $z 0
990    __
$a 20130424 $b ABA008
991    __
$a 20170524102608 $b ABA008
999    __
$a ok $b bmc $g 979274 $s 814394
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2012 $b 2012 $d 369086 $i 2090-6579 $m Case reports in hematology $n Case Rep Hematol $x MED00181388
GRA    __
$a NT12218 $p MZ0
LZP    __
$a Pubmed-20130424

Najít záznam

Citační ukazatele

    Možnosti archivace